Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

Inclusion criteria

• To be eligible for the study, patients should fulfill all the following criteria:

• Fully understand the study purpose, and understand the pharmacological effects and potential adverse reactions of the drug, voluntarily signed written informed consent according to the declaration of Helsinki.
• Age ≥18 and ≤ 50, healthy male subjects
• Weigh ≥ 50 kg and ≤ 100 kg， BMI≥ 19 and ≤ 28 kg/m2
• All the system test result within the normal range, or abnormal test results without clinical significance judged by the investigator.
• The subjects must agree to use effective contraceptive measures during the study treatment and for 6 months after receiving last does of study drug (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous)

Exclusion criteria

• Patients should not enter the study if any of the following exclusion criteria are fulfilled:

• Medical history of high blood pressure or abnormal blood pressure at screening/baseline(Double confirmed systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg within one day)
• Proteinuria with clinical significance judged by the investigator (routine urine examination, urine protein 2 + and above) or a history of proteinuria.
• Any prior VEGF(vascular endothelial growth factor) and VEGFR(Vascular Endothelial Growth Factor Receptor) antibody or protein treatment within one year.
• Any biological products or a live virus vaccine treatment within 3 months , or any monoclonal antibodies within 12 months before the first dose of study drug.
• History or evidence of inherited bleeding diathesis or coagulopathy or thrombus.
• History of digestive tract perforation or digestive tract fistula.
• Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 2 months prior to randomization or anticipation of need for major surgery during the course of the study or 2 months after last dose of the study drug.
• Use Rx or OTC drugs or nutritional health products within 5 half-lives or within 2 weeks before the first dose of study drug (According to the longer time).Herbal supplements need to stop at 28 days before the first dose of study drug.
• Positive hepatitis b surface antigen (HBsAg), hepatitis c virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody or syphilis
• Known hypersensitivity to Bevacizumab or any excipients
• Known allergic disease or allergic constitution
• History of blood donation within 3 months before the first dose of study drug
• Treatment with any other investigational agent or participation in another clinical trial within 3 months prior to screening
• History of alcoholism or drug abuse within 12 months prior to screening; Subjects cannot temperance within 72 hours before study drug infusion and during the whole study
• History of mental illness
• Anticipated of partner pregnancy during the study.
• Incompliance to the clinical study protocol during the study.
• Other conditions that the investigator thinks unsuitable in this study